Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-015349
Filing Date
2024-11-12
Accepted
2024-11-12 17:10:23
Documents
64
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cycc-20240930x10q.htm   iXBRL 10-Q 1518193
2 EX-31.1 cycc-20240930xex31d1.htm EX-31.1 14613
3 EX-31.2 cycc-20240930xex31d2.htm EX-31.2 15145
4 EX-32.1 cycc-20240930xex32d1.htm EX-32.1 5076
5 EX-32.2 cycc-20240930xex32d2.htm EX-32.2 5145
6 GRAPHIC cycc-20240930x10q001.jpg GRAPHIC 19511
7 GRAPHIC cycc-20240930x10q002.jpg GRAPHIC 33401
  Complete submission text file 0001558370-24-015349.txt   6304496

Data Files

Seq Description Document Type Size
8 EX-101.SCH cycc-20240930.xsd EX-101.SCH 47415
9 EX-101.CAL cycc-20240930_cal.xml EX-101.CAL 36242
10 EX-101.DEF cycc-20240930_def.xml EX-101.DEF 230281
11 EX-101.LAB cycc-20240930_lab.xml EX-101.LAB 368733
12 EX-101.PRE cycc-20240930_pre.xml EX-101.PRE 317180
67 EXTRACTED XBRL INSTANCE DOCUMENT cycc-20240930x10q_htm.xml XML 861993
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-50626 | Film No.: 241449781
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)